BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

798 related articles for article (PubMed ID: 15308613)

  • 1. Comparison of the pharmacological effects of a novel selective androgen receptor modulator, the 5alpha-reductase inhibitor finasteride, and the antiandrogen hydroxyflutamide in intact rats: new approach for benign prostate hyperplasia.
    Gao W; Kearbey JD; Nair VA; Chung K; Parlow AF; Miller DD; Dalton JT
    Endocrinology; 2004 Dec; 145(12):5420-8. PubMed ID: 15308613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ockham's razor and selective androgen receptor modulators (SARMs): are we overlooking the role of 5alpha-reductase?
    Gao W; Dalton JT
    Mol Interv; 2007 Feb; 7(1):10-3. PubMed ID: 17339601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-androgenic effects of S-40542, a novel non-steroidal selective androgen receptor modulator (SARM) for the treatment of benign prostatic hyperplasia.
    Nejishima H; Yamamoto N; Suzuki M; Furuya K; Nagata N; Yamada S
    Prostate; 2012 Oct; 72(14):1580-7. PubMed ID: 22430536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
    Bartsch G; Rittmaster RS; Klocker H
    Eur Urol; 2000 Apr; 37(4):367-80. PubMed ID: 10765065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
    Bartsch G; Rittmaster RS; Klocker H
    World J Urol; 2002 Apr; 19(6):413-25. PubMed ID: 12022710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the effects of the 5 alpha-reductase inhibitor finasteride and the antiandrogen flutamide on prostate and genital differentiation: dose-response studies.
    Imperato-McGinley J; Sanchez RS; Spencer JR; Yee B; Vaughan ED
    Endocrinology; 1992 Sep; 131(3):1149-56. PubMed ID: 1324152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chrysophanic acid reduces testosterone-induced benign prostatic hyperplasia in rats by suppressing 5α-reductase and extracellular signal-regulated kinase.
    Youn DH; Park J; Kim HL; Jung Y; Kang J; Jeong MY; Sethi G; Seok Ahn K; Um JY
    Oncotarget; 2017 Feb; 8(6):9500-9512. PubMed ID: 27880726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of spontaneous and androgen-induced prostate growth by a nonhypercalcemic calcitriol analog.
    Crescioli C; Ferruzzi P; Caporali A; Mancina R; Comerci A; Muratori M; Scaltriti M; Vannelli GB; Smiroldo S; Mariani R; Villari D; Bettuzzi S; Serio M; Adorini L; Maggi M
    Endocrinology; 2003 Jul; 144(7):3046-57. PubMed ID: 12810561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of 5alpha-reductase in rat prostate reveals differential regulation of androgen-response gene expression by testosterone and dihydrotestosterone.
    Dadras SS; Cai X; Abasolo I; Wang Z
    Gene Expr; 2001; 9(4-5):183-94. PubMed ID: 11444528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 5alpha-reductase activity in the prostate.
    Steers WD
    Urology; 2001 Dec; 58(6 Suppl 1):17-24; discussion 24. PubMed ID: 11750244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the Pharmacological Effects of a Novel Selective Androgen Receptor Modulator (SARM), the 5alpha-Reductase Inhibitor Finasteride, and the Antiandrogen Hydroxyflutamide in Intact Rats: New Approach for Benign Prostate Hyperplasia (BPH).
    Seftel A
    J Urol; 2005 Apr; 173(4):1279. PubMed ID: 15758780
    [No Abstract]   [Full Text] [Related]  

  • 12. A novel selective androgen receptor modulator (SARM) MK-4541 exerts anti-androgenic activity in the prostate cancer xenograft R-3327G and anabolic activity on skeletal muscle mass & function in castrated mice.
    Chisamore MJ; Gentile MA; Dillon GM; Baran M; Gambone C; Riley S; Schmidt A; Flores O; Wilkinson H; Alves SE
    J Steroid Biochem Mol Biol; 2016 Oct; 163():88-97. PubMed ID: 27106747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selectivity of finasteride as an in vivo inhibitor of 5alpha-reductase isozyme enzymatic activity in the human prostate.
    Span PN; Völler MC; Smals AG; Sweep FG; Schalken JA; Feneley MR; Kirby RS
    J Urol; 1999 Jan; 161(1):332-7. PubMed ID: 10037433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative study of human steroid 5alpha-reductase isoforms in prostate and female breast skin tissues: sensitivity to inhibition by finasteride and epristeride.
    Ranjan M; Diffley P; Stephen G; Price D; Walton TJ; Newton RP
    Life Sci; 2002 May; 71(2):115-26. PubMed ID: 12031682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential effect of finasteride on the tissue androgen concentrations in benign prostatic hyperplasia.
    Habib FK; Ross M; Tate R; Chisholm GD
    Clin Endocrinol (Oxf); 1997 Feb; 46(2):137-44. PubMed ID: 9135694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective estrogen receptor modulators regulate stromal proliferation in human benign prostatic hyperplasia by multiple beneficial mechanisms--action of two new agents.
    Kumar R; Verma V; Sarswat A; Maikhuri JP; Jain A; Jain RK; Sharma VL; Dalela D; Gupta G
    Invest New Drugs; 2012 Apr; 30(2):582-93. PubMed ID: 21181231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potency of a novel saw palmetto ethanol extract, SPET-085, for inhibition of 5alpha-reductase II.
    Pais P
    Adv Ther; 2010 Aug; 27(8):555-63. PubMed ID: 20623347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cynanchum wilfordii Ameliorates Testosterone-Induced Benign Prostatic Hyperplasia by Regulating 5α-Reductase and Androgen Receptor Activities in a Rat Model.
    Lee G; Shin J; Choi H; Jo A; Pan S; Bae D; Lee Y; Choi C
    Nutrients; 2017 Sep; 9(10):. PubMed ID: 28953224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of transforming growth factor-beta1, -beta2, and -beta3 in androgen-responsive growth of NRP-152 rat prostatic epithelial cells.
    Lucia MS; Sporn MB; Roberts AB; Stewart LV; Danielpour D
    J Cell Physiol; 1998 May; 175(2):184-92. PubMed ID: 9525477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological effects of the lipidosterolic extract of Serenoa repens (Permixon) on rat prostate hyperplasia induced by hyperprolactinemia: comparison with finasteride.
    Van Coppenolle F; Le Bourhis X; Carpentier F; Delaby G; Cousse H; Raynaud JP; Dupouy JP; Prevarskaya N
    Prostate; 2000 Apr; 43(1):49-58. PubMed ID: 10725865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.